Dendritic cells (DC) as potent antigen-presenting cells (APC) and T cells as effector cells play an essential role in the pathophysiology of both graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactions after transplantation. Therefore, we determined the kinetics of DC and T-cell chimerism establishment after allogeneic hematopoietic cell transplantation (AHCT) in a group of 144 patients, using fluorescence-activated cell sorting (FACS) or magnetic cell sorting (MACS) followed by FISH or STR-PCR analysis for chimerism evaluation. In all, three cell lines investigated (CD3 þ T cells, CD11c þ DC1 and CD123 þ DC2), we found a rapid and consistent establishment of complete donor chimerism (CDC) in over 70% of all patients during the first 6 weeks after AHCT. The rate of patients with CDC increased significantly over time within the first year after transplantation. A related donor (P ¼ 0.004) as well as an underlying lymphatic leukemia (P ¼ 0.03) were found to be significantly associated with development of MC in T cells. No significant correlation between DC or T cell chimerism and GvHD or relapse was detected. Our results thus demonstrate a fast and stable CDC in DC1, DC2 and T cells after AHCT that continuously increases over time in nearly all patients.
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Introduction
Allogeneic hematopoietic cell transplantation (AHCT) is still associated with a significant risk of morbidity and mortality. The most frequently observed transplant-related complications are graft-versus-host disease (GvHD), graftrejection, opportunistic infections and veno-occlusive disease (VOD). Relapse of the underlying malignant disease represents another major cause of death. 1 Since detection of the chimeric state of patients after AHCT became possible, there have been several controversial studies concerning the impact of chimerism establishment on parameters of transplant outcome like GvHD, graft-rejection or relapse. [2] [3] [4] [5] Most of the trials analyzed either the leukocyte chimerism in the peripheral blood or bone marrow chimerism with different cytogenetic or molecular biological techniques [6] [7] [8] [9] with no standardization on frequency and methods of analysis or interpretation of the detected results. 10 More recently, the chimerism of distinct hematopoietic cell lines has become a focus of research, 5, 11 especially of those cell lines that seem to play an important role in the pathophysiology of GvHD and graft-versus-leukemia reactions (GvL), for example, T cells and dendritic cells (DC). 12, 13 In development of GvHD, potent host antigen-presenting cells (APC) like DC seem to lead to an activation, proliferation and differentiation of allogeneic native donor T cells, resulting in damage of host tissues via release of cytokines (TNF-a, IL-1) as well as through unspecific (monocytes, NK cells) and specific (CD8 þ T cells) cellular cytotoxicity. [14] [15] [16] [17] At least two distinct subsets of DC in the peripheral blood have been described, with different immunological and also functional characteristics. 18 Myeloid DC (DC1) effectively activate alloimmunological native T cells leading to a Th1 differentiation. In contrast, the plasmacytoid DC (DC2) are poor activators of allogeneic native T cells, resulting in Th2 differentiation in the interaction with CD4 þ T helper cells. [19] [20] [21] T cells polarized to the T1 phenotype are thought to mediate cytotoxic effects of graft-versus-host reactions by cytokines like IL-2 and INF-g, whereas T2 polarized T cells seem to have anti-inflammatory or even GvHD-protecting functions (e.g. via the release of cytokines like IL-4 or IL-10). [22] [23] [24] Only limited data are available regarding the chimerism kinetics of DC and T cells after AHCT. Previously, Nachbaur et al. 25 analyzed the chimerism of monocytederived blood dendritic cells after cultivation with GM-CSF, IL-4 and TNF-a. Other investigators used DC isolated directly from peripheral blood for chimerism analysis and postulated an impact of DC chimerism on GvHD and relapse, but DC were separated with different immunological methods and at various time points after AHCT. 13, 26, 27 In this prospective trial, we determined the reconstitutional dynamics of DC1, DC2 and CD3 þ T cells in peripheral blood at the time of engraftment, as well as 6 and 12 months after AHCT. Additionally, chimerism results were also correlated with patients' baseline characteristics and with outcome parameters after AHCT like survival, relapse and GvHD.
Patients and methods

Study population
Blood samples from 144 patients (16 years of age and older) with different hematological disorders receiving AHCT were analyzed between April 1999 and October 2002. Patients were observed up to 12 months after AHCT. Patient and transplantation characteristics are summarized in Table 1 . Signed informed consent was obtained from all patients or their legal representatives allowing analysis of all clinical and laboratory data mentioned in this paper.
Trial design
This was a single-center (Jose´-Carreras Transplantation Unit, University of Munich, Germany), prospective study evaluating the kinetics of peripheral DC and T cell chimerism after AHCT. No exclusion criteria were defined.
Transplantation course
Until discharge, appearance and severity of GvHD and occurrence of relapse were documented daily. In the outpatient clinic the clinical course was documented weekly.
Acute GvHD (aGvHD: grades I-IV) and chronic GvHD (cGvHD: limited disease/extensive disease) were graded by clinical and biochemical criteria 28, 29 and confirmed by biopsy in a minority of patients. GvHD patients with aGvHD (4grade I) received first line standard therapy with prednisolone (maximum 3 mg/kg/day). Corticosteroid treatment was reduced (10% of dosage every 3 days) as soon as GvHD was controlled.
GvHD prophylaxis was given as follows: Application of cyclosporin A (CsA) was started by continuous infusion on day À1 in a dose of 5 mg/kg, reduced to 3 mg/kg on day þ 5 and switched to oral application on day 28. Doses were adapted to CsA plasma levels aimed at 150-200 ng/ml. CsA was tapered and discontinued after 2-3 months according to the clinical status of the patients. Mycophenolic acid (MPA) was started in a dose of 4 Â 7.5 mg/kg on day 0. MPA was discontinued after day þ 30. Methotrexate (MTX) was given in a dose of 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3 and þ 6 (or þ 7 for haploidentical HSCT, respectively). Antithymocyte globulin (ATG) was applicated in a dose of 10-30 mg/kg for 3-5 days within the conditioning regimen (Table 1) .
Relapse after AHCT was defined as hematologic, cytogenetic or molecular signs of recurring disease.
Blood sampling and assessments
During the post transplant period citrated blood samples were obtained daily at 0600 within the routine blood 2 for 4 days) combined with total body irradiation (2-4 Gy for 1 day, dose rate 4.5 cGy/min), and intravenous cyclophosphamide (40 mg/kg for 2-3 days) or conventional chemotherapy for second stem cell infusion (same donor) because of relapse or engraftment rejection (no ATG, highdose cyclophosphamide, TBI or busulfan).
sample collection via a central venous line for detection of peripheral DC (leukocytes 4100/ml until engraftment). Citrated blood samples for DC chimerism analyses were collected at the time of engraftment as soon as DC exceeded 0.1% of all leukocytes. Blood samples for DC chimerism analyses 6 and 12 months after HSCT were taken from a peripheral vein within the course of routine blood sample collections in the outpatient department. For T cell chimerism analysis, 50 ml heparinized blood was collected on approximately day þ 30 after AHCT via a central venous line, blood samples 6 months after AHCT were taken from a peripheral vein.
Detection of peripheral DC
Freshly drawn citrated whole blood was incubated with PerCP-conjugated anti-HLA-DR, FITC-conjugated antilineage 1 (anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20 and anti-CD56), APC-conjugated anti-CD11c and PE-conjugated anti-CD123. PE-conjugated IgG 1 (mouse) and APC-conjugated IgG 2a (mouse) served as isotype controls (Becton Dickinson Immunocytometry, San Jose, CA). After erythrocyte lysis (Becton Dickinson, Heidelberg, Germany) and centrifugation, the supernatant containing the lysated erythrocytes was removed. The sample was washed once and resuspended in PBS buffer for flow cytometric analysis. DC1 were identified as CD11c þ , HLA-DR þ and lineage1 negative cells while DC2 were identified as CD 123 þ , HLA-DR þ and lineage1 negative cells. Fluorescence intensity of 20 000 cells per sample was determined on a FACSCalibur flow cytometer running CELLQUEST software (Becton Dickinson, Heidelberg, Germany). The amount of DC1 and DC2 was expressed as percentage of total leukocyte count.
Isolation of peripheral DC
As soon as DC1 or DC2 exceeded a percentage of 0.1% of all leukocytes, DC were isolated from peripheral blood via fluorescent activated cell sorting. As a first step, mononuclear cells (MNC) were isolated by density centrifugation over Ficoll (PAA Laboratories GmbH, Linz, Austria) for 20 min at room temperature. The upper fraction containing the MNC was carefully removed and washed twice with PBS. Resuspended cells were incubated with anti-HLA-DR, antilineage1, anti-CD11c and anti-CD123, as described above, for 15 min at 41C. Cells were washed again and resuspended in PBS for cell sorting. DC1 (HLA-DR þ , lineage1À, CD11c þ ) and DC2 (HLA-DR þ , lineage1À, CD123 þ ) were identified and sorted into separate tubes by a FACSVantage SE cell sorter (Becton Dickinson, Heidelberg, Germany). The purity of isolated DC was controlled by flow cytometric analysis and constantly remained 495%.
Isolation of CD3 þ T cells T cells from peripheral blood were isolated with CD3 microbeads based on a MACS system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). MNC were separated from 50 ml heparinized blood by density centrifugation (Ficoll, PAA Laboratories GmbH, Linz, Austria) as described above. MNC resuspended in PBS were incubated for 15 min at 41C with CD3 microbeads (20 Chimerism analysis by fluorescent in situ hybridization (FISH) FISH was used for chimerism analyses after sex-mismatched transplantations. After creating a cytospin of freshly isolated DC or T cells (Cytocentrifuge: Shandon GmbH, Berlin, Germany), cells were fixed with methanol/ glacial acetic acid (3:1; Merck KG, Darmstadt, Germany) and brought through ethanol in rising concentrations (70-80-90-100%) afterwards. After application of sex chromosome-specific probes (CEP X Spectrum Orange and CEP Y Spectrum Green, Vysis GmbH, Bergisch Gladbach, Germany), preparations were hybridizated at 761C for 3 min and then kept at 371C for 24 h. Cells were washed at 751C and denaturated using SCC (sodium chloride and citrate, Merck KG, Darmstadt, Germany) containing NP 40 (Vysis GmbH, Bergisch Gladbach, Germany). After coating with diamidino-phenylindole (DAPI 125 ng/ml; Vysis GmbH, Bergisch Gladbach, Germany), a minimum of 100 interphase nuclei was evaluated under a fluorescence microscope (Axioscope 20, Carl Zeiss, Jena, Germany).
Chimerism analysis by polymerase chain reaction (PCR)-based short tandem repeat (STR) typing Chimerism analysis after sex-matched AHCT was performed by PCR-based STR typing. This method previously showed a very good correlation with the FISH technique. 30 DC or T cell DNA was isolated using the chelex method. 31 For each analysis, approximately 1 ng DNA was amplified using a multiplex kit (AmpFlSTR Profiler Plus Kit, Applied Biosystems, Weiterstadt, Germany) allowing the investigation of the 9 STR loci D3S1358, VWA, FGA, D8S1179, D21S11, D18S51, D5S818, D13S317 and D7S820. All loci show 4 bp repeats. Electrophoresis was performed in an ABI 310 capillary electrophoresis system (Applied Biosystems, Weiterstadt, Germany). For comparison, the original STR profile of the patient was determined via DNA isolated from mononuclear cells before AHCT and/or via DNA isolated from oral mucosa after AHCT, respectively. 
Definitions of qualitative and quantitative chimerism
Statistical analysis
Relapse-free and overall survival was determined by the Kaplan-Meier method, differences between groups were analyzed using the log rank test. All statistical tests were two-tailed, P-values below 0.05 being regarded as significant. Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS for Windows 10.0, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and transplantation-associated complications
The overall incidence of clinically relevant acute GvHD (grade II-IV) in this population was 50.0%, aGvHD mainly involved skin (54.8%), skin/gut (21.9%) and skin/ gut/liver (12.3%). Mean time of GvHD onset was day þ 22 (s.d. 12.9). Grade II aGvHD developed in 23 patients (16.0%), grade III in 34 patients (23.6%) and grade IV in 15 patients (10.4%). Chronic GvHD was found in 27.1% of all patients, with 17 patients (11.8%) having limited disease and 22 patients (15.3%) having extensive cGvHD. An early relapse after AHCT was diagnosed in 25 patients (17.4%) within the observation period of 12 months. The 1-year mortality rate was 29.9% (43 patients) with the main causes of death being relapse (17 patients), sepsis (12 patients) and GvHD (12 patients).
Kinetics of blood chimerism in DC subsets and CD3 þ T cells after AHCT Chimerism analysis at the time of engraftment. Mean time point of DC chimerism analysis was day þ 24 (s.d. 13.7) after AHCT. At the day of cell sorting for chimerism analysis, mean value for DC1 (% of leukocytes) in the peripheral blood was significantly higher than the value for DC2 (0.78 vs 0.43%, Po0.01), resulting in higher numbers of isolated DC1 than DC2 (mean: 14 Table 2C .
Patients with differences in the chimerism of distinct hematopoietic cell lines after AHCT At the time of engraftment, DC1 and DC2 chimerism was simultaneously monitored in 36 patients at the same day. Twenty-five patients (69.4%) showed CDC in DC1 as well as in DC2, five patients (13.9%) had MC in both DC subpopulations, three patients (8.3%) were found to have MC in DC1 and CDC in DC2, two patients (5.6%) CDC in DC1 and MC in DC2 and in one patient (2.8%) no chimerism was detectable either in DC1 or in DC2. After 6 months, AHCT, 19 patients were analyzed in both DC subpopulations: 16 (84.2%) had CDC in both DC subsets. One patient (5.3%) showed MC in DC1 and CDC in DC2, Table 2 Engraftment kinetics in DC and T cell chimerism during the first year after AHCT: (A) DC and T cell (TC) chimerism at engraftment; (B) DC and TC chimerism six months after AHCT; (C) DC chimerism twelve months after AHCT (A) Engraftment Patients with differences between DC1 and DC2 chimerism. At the time of engraftment, five patients showed different results in the chimerism of the two peripheral blood DC subsets analyzed, three of them developed clinically significant aGvHD. None of these five patients relapsed during our observation period of 12 months. Of 19 patients monitored 6 months after AHCT, two had differences between DC1 and DC2: in one patient MC of DC1 and CDC of DC2 was detected by FISH on day þ 286, whereas peripheral blood leukocytes on the same day showed CDC. On day þ 340 DC1, DC2 and peripheral blood all revealed a CDC. The patient neither developed GvHD nor a relapse of her CML. The second patient (MDS) showed CDC in DC1 and MC in DC2 (STR-PCR) on day þ 153. All chimerism analyses on bone marrow (day þ 96 and þ 356) and T cells (day þ 177) confirmed CDC, the patient developed mild cGvHD.
Patients with no chimerism in peripheral blood DC subsets. At engraftment, three patients were found to have no chimerism in at least one subset of peripheral blood DC. In one patient with CLL only host features were detectable in DC2 by STR-PCR on day þ 21, bone marrow (day þ 80), peripheral blood (day þ 148) and also T cells (day þ 92 and þ 250) showed MC. No GvHD or relapse occurred during the observation period. In a second female patient with AML only host DC1 and DC2 were detectable by FISH on day þ 21 after AHCT. The chimerism analysis of peripheral blood done on the same day showed CDC, with leukocytes exclusively of male donor origin. The patient developed severe aGvHD grade III of the skin and died on day þ 58 in complete remission due to cerebral microangiopathy. The third patient (ALL) showed only host features on STR-PCR analysis of DC2 on day þ 41, bone marrow and T cells were of complete donor origin (CDC) on day þ 64. DC2 chimerism converted to a CDC in a control analysis on day þ 99. No GvHD occurred, the patient died on day þ 195 because of relapse.
In one ALL patient, still 6 months after AHCT a lack of donor chimerism in DC was found. DC1 as well as DC2 showed no chimerism in FISH analysis performed on day þ 189. Corresponding chimerism results in this patient at engraftment were: CDC in DC2 (DC1 not done), MC in T cells and also MC in bone marrow. Acute GvHD grade III of the skin developed on day þ 11, no cGvHD or relapse was diagnosed during the first 12 months after AHCT.
Course of peripheral blood chimerism during the first year after AHCT Out of 29 patients showing CDC in DC1 at engraftment, nine patients were re-evaluated again after 6 and/or 12 months: all these patients still remained complete donor chimeric. In one patient, a MC in the DC1 at engraftment converted into a CDC after 6 months. In another patient, the mixed chimeric state in DC1 at engraftment was still detectable after 6 months. In the subset DC2, 33 patients remained at a CDC when analyzing them again after 6 and/ or 12 months after AHCT. Out of the 20 patients with MC of DC2 at engraftment, eight patients were re-evaluated again after 6 months where all of them had converted to CDC. Of the 32 patients with CDC in T cells at engraftment, 14 patients were reanalyzed 6 months later and all of them remained at the state of CDC. Three patients with a T cell MC converted into a CDC at the time point of 6 months after AHCT.
Associations between baseline patient characteristics and chimerism In DC1 and DC2 no influence of different pretransplantation parameters on the results of chimerism testing after AHCT was observed (Table 3) . Patients undergoing a myeloablative conditioning regimen had a higher proportion of CDC at engraftment (in both DC subpopulations) compared to patients with reduced-intensity conditioning, Table 3 Correlation between DC chimerism and baseline patient characteristics but this was not statistically significant (DC1: P ¼ 0.07, DC2: P ¼ 0.12).
As shown in Table 4 , the only significant pre-transplantation factors for developing mixed or complete T-cell chimerism were relationship of donor (related vs unrelated, P ¼ 0.004) and type of underlying leukemia (myeloid vs lymphatic, P ¼ 0.03).
Correlation of DC and T cell chimerism at engraftment with clinical outcome after AHCT Neither, DC1 and DC2 chimerism at the time of engraftment had a significant influence on the outcome after AHCT regarding relapse-free and overall survival in this population. For DC1 chimerism there was also no correlation with incidence or severity of acute or chronic GvHD (data not shown). For patients with MC of DC2 at engraftment, only a nonsignificant trend towards a higher incidence of cGvHD was observed (CDC vs MC: 31 vs 56%).
Concerning T cell chimerism, there was no statistical difference on relapse-free and overall survival between the groups with CDC and MC at engraftment. Also no significant differences regarding time of onset, incidence and severity of acute or chronic GvHD between patients with CDC and MC of T cells were detectable (data not shown).
Discussion
In this prospective trial, chimerism analyses of dendritic cells as well as of CD3 þ T cells, isolated directly from peripheral blood, were performed in a large group of recipients of allogeneic hematopoietic stem cells. One third of patients received a previous myeloablative conditioning regimen while the remaining two thirds received a conditioning regimen of reduced intensity ('nonmyeloablative'). Incidence of aGvHD and cGvHD was quite high in this group of 144 patients undergoing AHCT.
Our findings show that there is a consistent and rapid establishment of CDC in all analyzed subsets of leukocytes (DC1, DC2 and T cells) in more than 70% of all patients within the first 3-6 weeks after AHCT. These data correlate with in vitro findings, showing a median duration of about 14 days for generating dendritic Langerhans cells out of CD34 þ hematopoietic precursor cells. 32 Other groups already confirmed these findings in vivo, showing a rapid DC engraftment after autologous as well as after allogeneic transplantation. 13, 33, 34 Baron et al. 35 recently reported a rapid development of a high degree of quantitative donor chimerism in several peripheral blood cells lines after AHCT (e.g. in T cells: donor origin of about 70% on day þ 14), but most of these patients remained mixed donor/ host chimeras (with a progressive increase in donor cell counts over time) for up to 6 months after nonmyeloablative AHCT. However, this study did not investigate DC chimerism. On the other hand, we were also able to identify a small subset of patients with a lack of donor chimerism after engraftment as well as up to 6 months after AHCT. These patients had variable clinical characteristics and also often different results in subpopulation analyses of leukocyte chimerism in peripheral blood or bone marrow chimerism. Thus, the clinical significance of a lack of donor chimerism in DC or T cells after AHCT remains unclear. Mixed chimerism was found in about 20% of all patients at engraftment and decreased significantly after 6 and 12 months, correlating with a rise in CDC in DC as well as in T cells (as shown in Figure 1 ). After 12 months, AHCT nearly all patients were found to have CDC in DC1 and DC2. No conversion of a CDC to a MC in this period of time was seen in all patients investigated.
Furthermore, we could show that there are also patients with differences between DC1 and DC2 chimerism. At the time of engraftment, five patients were detected with different results in DC1 and DC2 chimerism, three of them developed aGvHD and none of them experienced a relapse during the observation period. Thus, a difference between DC1 and DC2 chimerism at engraftment may not necessarily be associated with relapse. Interestingly, we also found patients in our population who had CDC in Table 4 Correlation between T cell (TC) chimerism and baseline patient characteristics CDC TC (n ¼ 32) MC TC (n ¼ 10) P blood leukocytes, bone marrow or T cells and simultaneously MC or even no chimerism in DC subpopulations. An explanation for these controversial results is difficult, but the low percentage of DC of blood leukocytes might be one explanation for this observed phenomenon.
By correlating chimerism results with patients' baseline characteristics, a statistically non-significant association between reduced intensity conditioning and MC was observed. Patients developing a MC in T cells more often had a related donor (P ¼ 0.004) and a lymphatic leukemia (ALL, CLL) as underlying disease (P ¼ 0.03), compared to patients with CDC in CD3 þ T cells. A possible explanation for this observation could be that patients with an unrelated donor experienced more often GvH and also GvL reactions and thus had higher levels of CDC in T cells at engraftment. In contrast to results of other groups, we found no significant correlation between MC of T cells at engraftment and the occurrence of GvHD or relapse. Mattson et al. previously reported an association between mixed T cell chimerism in 102 patients and a decrease in the risk of aGvHD, but no association between T cell MC and relapse was found in their population. 12 In a trial performed by Petersen et al. 36 donor T cell chimerism after AHCT increased significantly (in CD4 þ and CD8 þ T cells) with the occurrence of aGvHD. It remains unclear, if this increase plays an etiological role in the pathobiology of GvHD or is a consequence of a graft-versus-lymphohematopoietic effect against residual host T cells. Also no statistically significant correlation of MC in DC at the time of engraftment with survival, relapse or GvHD was found.
Up to now, it is still not clearly defined which APC (the one of donor or the one of host origin) are mainly involved in donor T cell activation and thus GvH and GvL reactions after AHCT. There is strong evidence that host-APC alone are sufficient to initiated GvH reactions, 15, 16, 37 but there are also data indicating a potential role for donor APC. 17, 22 As we show here, in most of the patients on this study (470%), a CDC in DC as well as in CD3 þ T cells was established early after AHCT. But, also in patients with DC exclusively of donor origin circulating in peripheral blood, GvH reactions were observed. In fact, we do not know if this complete blood chimerism correlates with the chimerism of APC and T cells in host tissues. There is, up to now, only one published paper that analyzed this APC chimerism directly in the tissues of the AHCT recipient. Hessel et al. 38 detected a mixed chimerism of Langerhans cells in the skin of all nine leukemia patients analyzed in their investigation, in one case even up to day þ 1.395 after AHCT. Consequently it is conceivable, that the chimerism in peripheral blood does not necessarily reflect the chimeric status of DC and T cells in host tissues.
A possibility to analyze the chimeric state of APC and T cells not only in peripheral blood or bone marrow, but also in host tissues (e.g. skin or liver) should therefore be an interesting technique to further assess the question if host DC are the key APC in the pathophysiology of GvH and GvL reactions. Thus, further trials are warranted assessing DC and also T cell chimerism not only in peripheral blood but also in clinically relevant host tissues.
